biotech · Bladder Cancer · Non Muscle Invasive Bladder Cancer · CGON
CG Oncology
CG Oncology is a biotech organization headquartered in Dallas, USA. It trades on NYSE under ticker CGON. Primary therapeutic focus areas include Bladder Cancer, Non Muscle Invasive Bladder Cancer, Transitional Cell Carci
Dallas, USA HQ
2010 Founded
187 Employees
Public company Type
CGON · NYSE Ticker
Company details
- Status
- Public
- HQ
- Dallas, USA
- Founded
- 2010
- Employees
- 187
- Programs
- 8
- Drugs
- 1
- Patents
- 5
CG0070 Adenovirus Vector
Phase 3 · mab · Transitional Cell Carcinoma
CG0070 Adenovirus Vector for Transitional Cell Carcinoma is a Phase 3 program (mab) at CG Oncology with 1 ClinicalTrials.gov record(s).
Internal code 12154
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CG Oncology
- Phase
- Phase 3
- Modality
- mab
- Indication
- Transitional Cell Carcinoma
- Status
- terminated
- Trials
- 1